The new news is good, but its not the driver. Be honest, the JPM comment that FDA has openly discussed Kynamro labeling
That underscores the whole bag of tricks. If true, then the rest of the data was welcome, such as site reactivity and flu like symptoms causing high drop outs, have been solved.
FDA approves, EMA will look really "out there" if they do not and the stock would not drop a penny in this setting (with FDA approval).
ISIS then moves through severe FH into less than severe and on into lipid maintenance. Using the ssRNAi they could become the lipid maintenance method of choice and with no side effects. And this is just one issue, one pathway.
The stock is severely undervalued, but so many have cheated investors with the pea shell game using antisense, I understand this is what investors have to suffer. The breakthrough (license) will shock and awe the shorts. They have no idea what is coming...